Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone ...